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Molecular imaging with PET, and certainly integrated PET-CT, combining functional and anatomical
imaging, has many potential advantages over anatomical imaging alone in the combined modality treat-
ment of lung cancer. The aim of the current article is to review the available evidence regarding PET with
FDG and other tracers in the combined modality treatment of locally advanced lung cancer. The following
topics are addressed: tumor volume definition, outcome prediction and the added value of PET after ther-
apy, and finally its clinical implications and future perspectives.
The additional value of FDG-PET in defining the primary tumor volume has been established, mainly in
regions with atelectasis or post-treatment effects. Selective nodal irradiation (SNI) of FDG-PET positive
nodal stations is the preferred treatment in NSCLC, being safe and leading to decreased normal tissue expo-
sure, providing opportunities for dose escalation. First results in SCLC show similar results. FDG-uptake on
the pre-treatment PET scan is of prognostic value. Data on the value of pre-treatment FDG-uptake to predict
response to combined modality treatment are conflicting, but the limited data regarding early metabolic
response during treatment do show predictive value. The FDG response after radical treatment is of prog-
nostic significance. FDG-PET in the follow-up has potential benefit in NSCLC, while data in SCLC are lacking.
Radiotherapy boosting of radioresistant areas identified with FDG-PET is subject of current research.
Tracers other than 18FDG are promising for treatment response assessment and the visualization of intra-
tumor heterogeneity, but more research is needed before they can be clinically implemented.
 2011 Elsevier Ltd. All rights reserved.Background
Lung cancer accounts for 219,000 new cancer cases and 159,000
deaths a year in the United States, representing 15% of cancer cases
and 28% of cancer deaths in 2009.1 As patients often present with
primary irresectable disease, the majority of patients with local-
ized disease is currently treated with multimodality treatment
using a combination of surgery, chemotherapy (CTx), radiotherapy
(RT) and targeted agents. Although survival has significantly im-
proved with combined modality treatment, still, about one third
of locally advanced lung cancer patients experience local failure
as their first site of relapse.2 Furthermore, these combined treat-




in@maastro.nl (P. Lambin),prohibiting further intensification of treatment. This could poten-
tially be overcome by targeted antitumor therapy with increas-
ingly conformal RT techniques and targeted agents. Furthermore,
progress is made in strategies directed at individualization and
early adaptation of therapy dependent on the treatment response,
which may lead to optimization of the therapeutic ratio in each
individual. After completion of curative treatment, improvement
of outcome could be accomplished by an early detection of local
progression, increasing the possibility for those patients to be of-
fered salvage therapy.
With the introduction of these techniques, however, accurate
definition of the tumor volume to be treated becomes increasingly
important. This emphasizes the need for imaging techniques en-
abling accurate definition of the presence and extent of tumor be-
fore, during and after curative treatment in cancers of the
respiratory tract. While CT and MRI are the most accurate imaging
modalities with respect to anatomical information, they often lack
the potential to distinguish between vital tumor and non-malig-
nant tissue. Here, molecular imaging with positron emission
tomography (PET), providing metabolic information, has additional
332 J. van Loon et al. / Cancer Treatment Reviews 37 (2011) 331–343value. Different radiopharmaceuticals have been evaluated for the
imaging of malignant tumors, of which 18F-fluorodeoxyglucose
(18F-FDG) is by far most commonly used. FDG-PET scanning uti-
lizes the difference in accumulation of FDG between normal and
cancerous tissues, based on an enhanced glucose metabolism in
cancer cells. Other PET tracers, visualizing specific molecular path-
ways in tumors such as proliferation (e.g. 11C-methionine, 11C-cho-
line, 18F-fluorothymidine) hypoxia (e.g. 18F-FMISO) or expression
of certain receptors (Her2Neu, EGFR) are increasingly being used
in the evaluation of malignancies.
Thus, metabolic imaging with PET, and certainly integrated PET-
CT, combining functional and anatomical imaging, has many po-
tential advantages over anatomical imaging alone in the combined
modality treatment of lung cancer. PET using FDG is at present
most widely applied in the clinical practice of non-small cell lung
cancer (NSCLC). Its use in small cell lung cancer (SCLC) is rapidly
emerging.
The aim of the current article is to review the available evidence
on the use of PET in the combined modality treatment of locally ad-
vanced lung cancer. For NSCLC and SCLC separately, the role of PET
imaging will be addressed with respect to the following topics:
1. Definition of the tumor volume to be treated, both with respect
to the primary tumor and the locoregional lymph nodes
2. Outcome prediction on basis of PET before or early after the
start of treatment, and the added value of PET after therapy
With regard to both these topics, the clinical implications of the
use of PET are addressed, and future perspectives are provided.
Because 18F-FDG is by far most commonly applied in clinical
practice, the majority of evidence comes from this tracer. There-
fore, where ‘‘PET’’ is used in this article, this refers to ‘‘18F-FDG-
PET’’, unless otherwise stated. Wherever other tracers have shown
additional value, or are regarded as promising in the near future,
they will be discussed.Search strategy
A comprehensive literature search was conducted using the
‘‘Pubmed’’ database. Included search terms were: ‘‘Non small cell
lung cancer’’, ‘‘Small cell lung cancer’’, ‘‘NSCLC’’, ‘‘SCLC’’, ‘‘Target
volume definition’’, ‘‘Delineation’’, ‘‘Gross tumor volume (GTV)’’,
‘‘Clinical target volume (CTV)’’, ‘‘Tumor heterogeneity’’, ‘‘Selective
nodal irradiation’’, ‘‘Prognostic value’’, ‘‘Outcome prediction’’, ‘‘Fol-
low-up’’, ‘‘Combined modality treatment’’, ‘‘Chemotherapy’’,
‘‘Radiotherapy’’ or ‘‘Radiation’’ in combination with ‘‘PET’’, ‘‘Posi-
tron emission tomography’’ or ‘‘Molecular imaging’’.
Reference lists of relevant articles were searched for further
studies.
Only publications in the English language and published online
before February 1, 2010 were included.Non-small-cell lung cancer (NSCLC)
NSCLC represents more than 80% of lung cancer cases.3 Com-
bined chemoradiotherapy is the standard treatment for locally ad-
vanced (stage III), inoperable NSCLC.4 The added value of PET to
select patients for combined modality treatment has been studied
extensively5–7, and it was shown that PET staging results in supe-
rior outcome due to stage migration: up to 30% of stage III patients
are diagnosed with distant metastases.8,9 This clearly affects pa-
tient outcome as it withholds toxic therapy in individuals who will
not benefit from it.
Below, we will discuss the role of PET in the RT planning and
evaluation of combined chemoradiotherapy for stage III NSCLC.Definition of the tumor volume to be treated
Primary tumor
Although FDG-PET has a high sensitivity for the detection of the
primary tumor, an important drawback is its lack of anatomic detail,
which limits its ability to define the exact tumor boundaries. The
spatial resolution of current PET scanners is limited to 4–6 mm10,
which is far lower than that of modern CT scanners, with a resolution
down to 1 mm. There are cases, however, where anatomic imaging
modalities such as CT are compromised in their ability to define
the exact tumor border, such as in patients with atelectasis or tumors
near the thoracic wall.11 Multiple studies have shown a large inter-
observer variation in delineation of the tumor on CT.11,12 This inter-
observer variation is significantly diminished by using the
information of a FDG-PET scan, co-registered with CT.13–16 Overall,
volumes delineated using PET-CT are smaller.14 Differences between
PET and CT were mainly found in the regions with atelectasis.14,17,18
Various quantitative methods have been developed for auto-
matic tumor delineation using PET instead of visual interpretation
of the PET signal. The most straightforward method uses an abso-
lute threshold of the standardized uptake value (SUV). The SUVmax
threshold of 2.5 is often used for this purpose.19 An absolute
threshold should be used with caution, however, as the SUV is
associated with considerable variety due to both technical and bio-
logical factors.20 An alternative method is the use of a relative
threshold, e.g. a certain percentage of the SUVmax. Recently, more
complex methods have been developed, including the application
of an individualized threshold based on the source-to-background
ratio (SBR) or the watershed clustering method.21–23 An example of
the difference in interobserver variation between manual and
autocontour based delineation is provided in Fig. 1. Nestle et al.
compared absolute (SUVmax P 2.5), relative (40% SUVmax) and indi-
vidual (SBR algorithm) quantitative methods and a visual interpre-
tation method with CT-volumes.24 There were large differences in
the resulting volumes, particularly in patients with a heteroge-
neous pattern of FDG-uptake.
Although autocontour based delineation methods have thus
proven their utility in reducing interobserver variability, all quan-
titative methods harbor the risk of including metabolic active but
not cancerous tissue in the GTV. Therefore, it has been suggested
that those methods should be used complementary to visual inter-
pretation, and not as a substitute for it.25,26
Ideally, validation of the delineated tumor volume should be
obtained by correlating it with the tumor volume at pathologic
examination, being the gold standard. The currently available data
are based on two-dimensional correlations in early stage dis-
ease.27–29 With the use of a relative threshold, a better correlation
was found for CT than for PET (correlation coefficient 0.87 vs.
0.77).27 Yu et al. found the best correlation with integrated PET-
CT based on an absolute threshold (SUVmax P 2.5).28 A correlation
coefficient of 0.90 was found between the maximal tumor diame-
ter obtained with SBR-based autodelineation and pathology.29
Promising attempts are made to develop a three-dimensional mod-
el, but results in large patient cohorts are to be awaited.30–32
The methods described above are aimed at an accurate defini-
tion of the gross tumor volume (GTV) in order to ensure that this
region is adequately covered by the RT treatment fields. Character-
istics associated with radioresistance, such as hypoxia, cell density
and proliferation, however, are known to be heterogeneous across
the tumor.33–35 FDG-PET scans may allow the identification of
therapy-resistant areas within the tumor. It would be logical to
selectively boost the radioresistant areas, whilst decreasing the
dose to the less resistant zones, resulting in higher tumor control
with similar side effects.36–39 It has been demonstrated that re-
gions with high FDG uptake prior to radiotherapy correspond well
with the location of recurrent/persistent tumor after sequential
Fig. 1. Example of a manual (a) and autocontour based (b) delineation of the primary tumor For autocontouring, the SBR based method was used. Arrows indicate changes in
interobserver variation in delineation between the two methods. Reprinted from: van Baardwijk A, Bosmans G, Boersma L, et al. PET-CT-based auto-contouring in non-small-
cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol
Phys 2007;68:771–778. Copyright 2010, with permission from Elsevier.
Fig. 2. Correlation between pre-treatment high FDG-uptake areas and location of residual disease. Representative FDG-PET-CT images of three patients pre- and post-
radiotherapy. The light gray lines indicate the 50% SUVmax FDG high-uptake area pre-radiotherapy. The dark lines indicate the residual metabolic-active areas post-
radiotherapy, also transposed on the pre-radiotherapy scan. Visual evaluation shows a large correspondence between the residual areas post-radiotherapy with the high FDG-
uptake areas pre-radiotherapy. Reprinted from: Aerts HJ, van Baardwijk AA, Petit SF, et al. Identification of residual metabolic-active areas within individual NSCLC tumors
using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol 2009;91:386–392. Copyright 2010, with permission from Elsevier.
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regions remain stable during a course of RT (Fig. 3).42 Thus, selec-
tive boosting of areas of assumed radioresistance identified with
FDG-PET before the start of RT appears to have a good rationale.
It remains important, however, to consider that other biologic
characteristics within the GTV, such as inflammation, may be asso-
ciated with increased FDG-uptake as well, that are not directly re-
lated to increased radioresistance.43Therefore, further research in
this field is strongly encouraged.
The additional value of FDG-PET scanning in defining the pri-
mary tumor volume is thus beyond doubt. However, the draw-
backs of FDG-PET should be kept in mind. Due to the poor
resolution, blurring does occur, particularly at the tumor edges.20
Those blurring effects at the tumor boundary are even more pro-
nounced by motion artefacts. Although the long acquisition time
of PET is disadvantageous with respect to defining an absolute tu-
mor edge and quantitating metabolic activity, it may have addi-
tional value in determining the extent of tumor motion. The
acquisition time of several minutes results in a tumor volume
incorporating the averaged position of the tumor over multiple
respiratory and cardiac cycles. In a phantom study, PET-based
treatment volumes resulted in an adequate coverage of the tumor,
while CT-based volumes harbored the risk of a geographical miss.44
Respiratory gating or 4D imaging techniques allow the incorpora-
tion of the extent of tumor movement, while optimizing image
quality and quantitation as the blurring effect is reduced.45 Those
techniques are presently being evaluated in clinical studies.45,46Microscopic disease extension
The poor spatial resolution of PET precludes a direct evaluation
of the presence and extent of microscopic disease around the mac-
roscopic tumor border. Definition of the area of potential micro-
scopic spread in patients treated with chemoradiotherapy is
important as this region should be covered in the radiation field.
The only way to quantitate microscopic spread beyond the tumor
border visible on imaging is by correlating imaging with the find-
ings at pathologic examination. Until now, this correlation has only
been performed between CT and pathology.47–49 Furthermore, no
correction was applied for deformation of the lung lobe after
surgery. Methods for the correlation of both PET and CT with
pathology, which do take into account deformation, are under
development.30,31 First results indicate an average microscopic
spread in vivo of 9 mm31, suggesting that currently applied mar-
gins might be too small to cover microscopic disease.
Lymph nodes
Accurate identification of nodal metastases has become of par-
ticular importance since routine elective nodal irradiation, i.e. the
prophylactic irradiation of clinically uninvolved lymph nodes, is
no longer recommended in NSCLC.50,51 FDG-PET has a higher sen-
sitivity and specificity for the detection of lymph node involvement
in NSCLC than CT (sensitivity: 83% vs. 62%; specificity: 97% vs. 91%,
respectively).52 Both PET- and CT-based selective irradiation of
involved lymph nodes has proven its safety in NSCLC, with the
occurrence of isolated nodal failures (INF) in less than 5% of
Fig. 3. Stability of high FDG-uptake areas during a course of RT PET-CT images of three patients before treatment (Day 0) and during treatment (Days 7 and 14). Lines indicate
60% of maximal standardized uptake value (SUVmax) threshold. Visual inspection showed that location of the hotspot remained at the same location during treatment;
however, the volume of the hotspot changed. Reprinted from: Aerts HJ, Bosmans G, van Baardwijk AA, et al. Stability of 18F-deoxyglucose uptake locations within tumor
during radiotherapy for NSCLC: a prospective study. Int J Radiat Oncol Biol Phys 2008;71:1402–1407. Copyright 2010, with permission from Elsevier.
Fig. 4. Example of the effects of RT planning with PET-CT compared to CT alone
Projection of the planning target volume (PTV) of a 66-yearold female with a large
cell carcinoma of the right lower lobe with pathological lymph nodes on CT scan in
areas 4R and 3R and on FDG-PET scan in area 7. Although the lung exposure was
lower with PET-CT than with CT (V20 25 vs. 30% and MLD 15.4 vs. 19.3 Gy,
respectively), the esophageal exposure was higher with PET-CT because of the
involvement of level 7 (MED 16.9 vs. 14.1 Gy, V55 18 vs. 4%, Dmax 60.1 vs. 58.6 Gy,
respectively, for PET-CT and CT). Reprinted from: De Ruysscher D, Wanders S,
Minken A, et al. Effects of radiotherapy planning with a dedicated combined PET-
CT-simulator of patients with non-small-cell lung cancer on dose limiting normal
tissues and radiation dose-escalation: a planning study. Radiother Oncol 2005;77:5-
10. Copyright 2010, with permission from Elsevier.
334 J. van Loon et al. / Cancer Treatment Reviews 37 (2011) 331–343patients.53–56 One study found INF in up to 15% with PET-based
SNI.57 However, the accuracy of the identification of lymph nodes
in this study was questionable, as only visual interpretation of
non-coregistered FDG-PET images was used. In general, the PET-
based treatment volumes are smaller than CT-based volumes.58,59
Selective nodal irradiation (SNI) has shown not only to be safe,
but also to result in a reduction of radiation fields based on CT,
and even further based on FDG-PET.55 A modeling study showed
that treating only FDG-positive mediastinal areas decreases radia-
tion exposure of the lungs and the esophagus sufficiently as to al-
low for radiation dose-escalation.55,59 An example of the difference
resulting from RT planning with PET-CT compared to CT alone is
illustrated in Fig. 4.
Although PET-defined SNI appears to be safe, ideally, patholog-
ical confirmation should be obtained. Pathological validation of
the CT-and PET-based nodal treatment volumes was performed
in 998 lymph nodal stations from 105 patients.60 The coverage
of all pathologic lymph nodes was 89% with PET-based treatment
volumes compared to 75% with CT (p = 0.005). Nevertheless, a
false negative rate with PET up to 14% has been reported in oper-
able patients.61 A possible explanation for the low amount of iso-
lated nodal failures is the incidental irradiation of clinically
negative lymph node stations through coverage by the beam pen-
umbra of conventional RT fields. The Michigan group showed that
risk factors of nodal metastases, such as a large tumor size and
central location, were associated with a considerable dose to the
high-risk nodal regions.62 Therefore, caution is warranted with
the application of new RT technologies, such as stereotactic body
radiotherapy (SBRT), intensity modulated radiotherapy (IMRT)
and particle therapy, as they are associated with a more conformal
dose distribution.Different methods can be used for delineation of the involved
lymph nodes on PET. Nestle et al. compared the nodal volumes
resulting from visual delineation and absolute (SUVmax P 2.5),
J. van Loon et al. / Cancer Treatment Reviews 37 (2011) 331–343 335relative (40% SUVmax) and individual (SBR-based) thresholds.63
There were no clinically relevant differences in resulting volumes.
SBR-based contouring of lymph nodes generally showed a good
correlation with pathology.29 Regardless of the delineation meth-
od, the question remains how to incorporate the lymph nodes in
the treatment volume. There are no data available on the micro-
scopic extension of disease outside lymph nodes. This residual
uncertainty can be overcome by encompassing the whole anatom-
ical mediastinal region in the treatment volume, as was done in the
Maastricht studies described above.55,58,59
As for the primary tumor, the exact anatomical localization of
the mediastinal lymph nodes may be blurred because of respira-
tory motion. Ideally, individually determined margins should be
applied to cover the lymph nodes in all respiratory phases, as there
is a large intra- and inter-individual variation in lymph node mo-
tion, not related to the motion of the primary tumor.64–66
Clinical implications and future perspectives
The incorporation of PET in RT planning has shown the potential
for dose escalation through a reduction of the radiation fields,
mainly because of avoidance of irradiating PET negative lymph
nodes.58,59,67 With individualized radiation dose escalation based
on normal tissue constraints, patients treated with sequential che-
moradiation had survival rates comparable to results with concur-
rent chemoradiation schedules while less toxicity was observed.68
These results imply that PET-based RT planning might ultimately
lead to higher cure rates, and randomized prospective studies are
warranted to investigate this further.
Further optimization of the treatment volume could be ob-
tained by accurate definition of the appropriate margin around
the delineated tumor to cover microscopic disease. This informa-
tion should become available from pathology correlation studies.
Recently, an increasing tendency has emerged to move away from
the concept of homogeneous irradiation. Studies have been per-
formed to investigate the feasibility of selectively boosting areas with
residual FDG-uptake after 40–60 Gy, with diverging results.69,70 Pro-
spective trials are awaited to investigate whether radiation dose
redistribution leads to better treatment outcome, for which prepara-
tions are currently being performed.37,71 In the studies mentioned be-
fore, 18FDG was used as a tracer for radioresistant areas. Other tracers,
e.g. for hypoxia (18F-FMISO, 18F-HX4) or proliferation (18F-FLT) could
be used complementary to or instead of FDG.72–76 These tracers de-
serve further investigation for this purpose.
Conclusion
FDG-PET has an important additional role to anatomic imaging
in defining the primary tumor volume. Automatic delineation with
adaptive techniques, such as SBR-based methods is to be preferred
above absolute thresholding. Models are under development that
correlate imaging findings with pathology in three dimensions.
These could finally allow validation of different thresholds for
SUV-based contouring and evaluation of microscopic spread and
intra-tumor heterogeneity. Selective boosting of radioresistant
areas identified with FDG-PET is subject of current research.
Selective irradiation of FDG-PET positive nodal stations is safe
and leads to decreased normal tissue exposure, providing opportu-
nities for dose escalation. With the increased use of more confor-
mal radiation techniques, the safety of PET-based SNI should be
re-evaluated. Disparities in treatment volumes resulting from dif-
ferent contouring methods are smaller than for the primary tumor.
Outcome prediction on basis of PET before or early after the start of
treatment, and the added value of PET after therapy
Despite the improved outcome of inoperable stage III NSCLC
achieved with combined chemoradiotherapy, the majority of inop-erable stage III NSCLC patients still show disease progression after
treatment, with 23–43% having an isolated local recurrence as their
first site of progression.77–81 As the treatment is associated with
considerable toxicity, it would be of great value to select patients
before or early during treatment, with the highest probability to
benefit from treatment and to adjust the treatment in the other pa-
tient group.
Early response assessment with conventional chest X-ray and
CT is limited by their poor discriminating capacity between resid-
ual tumor and treatment induced changes.82,83 PET scanning al-
lows for the assessment of changes in glucose consumption of
the tumor during chemo- and radiotherapy. Several studies have
shown a correlation between the SUV and tumor cell prolifera-
tion84–86, supporting the hypothesis that an early change in FDG
uptake has predictive value.
Prognostic value of pre-treatment PET
Most evidence regarding the prognostic value of pre-treatment
PET comes from studies in heterogeneous patient populations with
both early and late stage disease, treated with different modalities.
A meta-analysis was performed within the IASLC lung cancer stag-
ing project. 11/13 eligible studies in stage I–IV NSCLC identified a
high SUV as a poor prognostic factor for survival, with a combined
HR for survival of 2.27 (95% CI: 1.43–3.04) for low vs. high SUV.87
The threshold was variable between the studies, ranging from 5 to
20. Those differences are due to both technical and patient related
factors, such as different scanners, time intervals between injection
and scanning and fasting times. Furthermore, the relationship be-
tween SUV and prognosis is rather gradual than fixed at a single
cut-off point.
Regarding the ability of PET to predict response to combined
modality treatment, the first study in patients with advanced dis-
ease treated with (chemo-)radiotherapy showed a positive correla-
tion between the tumor to muscle ratio (TMR) and response, but no
significant correlation with outcome.88 Two later studies revealed
SUVmean and SUVmax to be significantly associated with overall sur-
vival.89,90 In the first population, both tumor grade and UICC stage
showed a stronger correlation with survival than the SUV89, while
in the second study, SUVmax was the strongest predictor.90 By con-
trast, the most recent study in the largest cohort of stage III and IV
NSCLC patients thus far (n = 214), did not show a significant rela-
tionship with survival.91 This study was not included in the IASLC
meta-analysis mentioned above.
Outcome prediction on basis of early PET response during combined
modality treatment
Because FDG is preferentially accumulated in viable tumor
cells92,93, FDG-PET imaging is an attractive method to visualize
early treatment response. In advanced NSCLC, the predictive value
of an early metabolic response to palliative chemotherapy, as well
as to radical treatment with (chemo)radiotherapy has been evalu-
ated. Prospective observational studies have consistently shown
that in advanced NSCLC treated with palliative chemotherapy,
the metabolic response after 1–3 cycles of chemotherapy is
strongly correlated with outcome.94–97
With respect to radical treatment, metabolic response to induc-
tion chemotherapy prior to radiotherapy or surgery in locally ad-
vanced NSCLC patients has been shown to correlate with
outcome in multiple studies.95,98–100 One study, however, did not
show a predictive value.101 While the evidence regarding the pre-
dictive value of a metabolic response to induction chemotherapy is
abundant, far less is known about its value early during the course
of radical treatment itself. Two studies investigated the predictive
value of response during radiotherapy alone or chemoradiation.
The first study was a pilot study in 15 patients treated with RT
alone or chemoradiotherapy. A significant correlation was found
336 J. van Loon et al. / Cancer Treatment Reviews 37 (2011) 331–343between the response after 45 Gy of RT and the response 3 months
after RT.102 The second study, investigating the predictive value of
response during concurrent chemoradiotherapy103, showed a sig-
nificant difference in long-term survival between patients with
and without a metabolic response after 3 weeks of concurrent che-
moradiotherapy. An overview of the studies evaluating outcome
prediction on basis of early PET response to combined modality
treatment is provided in Table 1. A study evaluating response dur-
ing radical RT revealed a large intra-patient heterogeneity in the
evolution of SUVmax during and after radical RT.104 Different time
patterns were seen for responders and non-responders, but due
to the limited patient numbers, the predictive value of the SUVmax
changes could not be assessed.
To make FDG response assessment a valuable tool in routine
clinical practice, a clear definition of response should be pre-
scribed, as the intra-patient variability of repeated tumor SUV-
measurements is in the range of 10–15%.105–107 Furthermore, early
response should be assessed at a fixed time interval. Ideally, the
interval should be short enough to switch to a potentially more
successful treatment as early as possible, but with a time interval
sufficient to allow for a reliable response assessment. In 1999,
the EORTC published consensus guidelines on which cut-off points
should be used to define response at different time intervals108,
which are still widely applied in clinical practice. Weber et al. de-
fined a metabolic response after the first cycle of chemotherapy as
a decrease in FDG uptake of more than twice the standard devia-
tion, calculated to be 20%. This definition correlated with final re-
sponse according to RECIST, as well as with time to progression
and overall survival.96 The Melbourne group demonstrated that vi-
sual response assessment on PET with the use of standardized re-
sponse criteria correlated with survival and was superior to
response assessment on CT using WHO response criteria.109 In
2009, the PET Response Criteria in Solid Tumours (PERCIST version
1.0) have been proposed resulting from a review of qualitative and
quantitative methods of metabolic response assessment.110 PER-
CIST recommends to correct SUV for lean body mass (SUL) as this
accounts for variations due to differences in body composition.
A comparison between the EORTC criteria and PERCIST is pro-
vided in Table 2. Overall and most importantly, the same definition
of response criteria should be used by different groups to be able to
compare metabolic response studies across different centers.
Concerning the type of measurement, semiquantitative meth-
ods, such as the relative change in SUV, appear to perform equally
well as more complex quantitative methods such as change in the
net-influx constants (Ki) or metabolic rate of glucose (MRglu).95–97
This facilitates the use of early PET response for outcome predic-
tion in daily clinical practice.
Added value of PET after combined modality treatment
The accuracy of PET after treatment is assumed to be lower than
at initial staging because of therapy induced inflammatory andTable 1
Prediction of outcome on basis of early PET response to combined modality treatment.
Study N Stage Timepoint of PETscan Radical treat
Hellwig (2004)99 47 IIB–III After induction therapya Surgery
Hoekstra (2005)95 47 IIIA 1 and 3 Cycles Surgery or R
Pottgen (2006)100 50 III 3 Cycles ChemoRT ± S
Kong (2007)102 15 I–III 45 Gy (chemo)RT
(Decoster) 200898 31 III 3 Cycles RT
Tanvetyanon (2008)101 89 I–III 2 Cycles Surgery
Zhang (2009)103 46 III 40–50 Gy ChemoRT
N, number of patients; NR, not reported; CMR, complete metabolic response; PMR, part
a Data on number of cycles are not provided. Induction therapy consisted of chemothperfusion changes.111 Nevertheless, PET still has a high accuracy
in detecting recurrent lung cancer, with a sensitivity up to 98%
and a specificity of 62–92%111–113, and is more accurate than CT
in the distinction of tumor from post-RT effects.109,114,115 Here,
the added value of a post-treatment PET is addressed with regard
to the prognostic value of a PET early after treatment and the role
of PET in the follow-up after combined modality therapy.
We identified four studies addressing the prognostic value of
PET after radical treatment in locally advanced NSCLC patients,
consisting of (chemo-)RT.79,88,104,116 Four studies evaluated the
predictive value of PET after induction chemoRT before sur-
gery.100,117–119 Details of the studies evaluating the prognostic va-
lue after radical (chemo)RT and the predictive value after induction
(chemo)RT are provided in Table 3. These studies were unambigu-
ous in their conclusion that the FDG response after radical treat-
ment has prognostic value. Mac Manus proved the superiority of
PET response above CT. Response on PET and CT was identical in
only 40% of patients. In multivariate analysis, only the PET re-
sponse was significantly associated with survival.109
Clear cut-offs should be prescribed to define the different prog-
nostic subgroups. In the aforementioned studies, however, there is
a large heterogeneity in the way FDG-uptake after therapy was
measured. Some studies reported an absolute threshold post-treat-
ment88,100,117,119, while others stratified patients according to the
relative change in SUV.79,104,109,116,118 In none of the studies a di-
rect comparison was made between the different methods. Until
more data are available we recommend the use of the EORTC crite-
ria for PET response108 for prognostic stratification, as the results of
the larger studies are mainly based on these criteria.
Another important aspect is the timing of the PET-CT. The med-
ian time interval in the studies described above was 14–70 days. It
is recommended to perform a PET-CT scan not earlier than 3–
6 months after treatment to avoid false positive results due to
post-therapy inflammatory changes.111,120 The time interval
should not be excessive either, as the final aim is to select patients
for further therapy. Hicks et al. observed no confounding effect
through post-RT inflammatory changes for response assessment
with a PET-CT scan performed 70 days after radical RT.121 As differ-
ent time-points have not been compared directly, we recommend
the use of the time point 70 days post-treatment.
It should be noted that the results described above only apply
for patients treated with conventional or hyperfractionated RT
with or without chemotherapy. In hypofractionated SBRT, where
3–5 large fractions are applied, persistently elevated SUVmax of
>3.5 have been described up to one year post treatment.122,123
These different findings may be explained by localized normal tis-
sue changes induced by SBRT, such as segmental atelectasis or fo-
cal fibrosis, not distinguishable from persistent or recurrent tumor.
PET in the follow-up of NSCLC could improve outcome when
progressive disease can be detected early enough to allow radical
retreatment. There are no convincing data supporting that earlyment Definition of cut-off Predictive value
SUVmax = 4 OS: yes
T Residual MRglu = 0.13 OS: yes
urgery NR Histopathologic tumor response: yes
CMR/PMR CMR/PMR 3 months after treatment: yes
CMR PFS: yes
OS: trend
30% Decrease in SUVmax OS: no
50% Decrease in SUVmax OS: yes
ial metabolic response; OS, overall survival; PFS, progression free survival.
erapy only or chemotherapy followed by RT.
Table 2





>25% Increase in SUV of tumor defined on pre-treatment
scan, or >20% increase in the longest dimension of FDG-
uptake, or Appearance of new FDG-uptake in metastatic
lesions
>30% Increase in SUL peak and absolute increase of SUL units P0.8 from baseline
scan in pattern typical of tumor and not of infection /treatment effect, or
Visible increase in extent of FDG-uptake (> 75% increase in total lesion
glycolysis), or




<25% Increase or <15% decrease in SUV of tumor defined on
pre-treatment scan, and <20% increase in the longest
dimension of FDG-uptake
No CMR, PMR or PMD
Partial Metabolic
Response (PMR)
>15% Decrease in SUV of tumor defined on pre-treatment
scan (after 1 cycle)
> 25% decrease in SUV of tumor defined on pre-treatment
scan (after >1 cycle)
>30% Decrease in SUL peak and absolute drop in SUL units P0.8 of the most
intense lesion before and after treatment (not necessarily the same lesion)
No new FDG-avid lesions typical of cancer
Complete Metabolic
Response (CMR)
Complete resolution of FDG-uptake within tumor defined on
pre-treatment scan, not distinguishable from surrounding
normal tissue
Complete resolution of FDG-uptake within measurable target lesion, less than
mean liver activity and indistinguishable from surrounding background blood-
pool levels
Disappearance of all other lesions to background blood-pool levels
No new FDG-avid lesions typical of cancer
SUL: Standardized uptake value corrected for lean body mass.
Table 3
Value of post-treatment PET.
Study N Stage Intervala Radical
treatment
Definition of threshold Prognostic value
Post (chemo)RT
Ichiya (1996)88 20 III–IV <3 weeksks RT or chemoRT TMR > 5 RFS: yes
Hebert (1996)166 12 NR NR RT CR, visually interpreted Probableb
Mac Manus (2005)79 88 I–III 70 days
(median)





20 I–III 71 days
(median)
RT or chemoRT CMR or PMR OS: yes
After Neoadjuvant treatment
Predictive value
Choi (1998)117 29 IIB–
IIIA
2 weeks ChemoRT MRglu 6 0.040 pTCP P 95%
Ryu, 2002119 26 III 2 wks ChemoRT SUVmean>3 Pathological complete response:
yes
Pottgen (2006)100 43 III NRc ChemoRT SUVmaxpost/SUVmaxpred=0.38–0.55 Histopathologic tumor
response: yes
Eschmann (2007)118 70 III 2 weeks ChemoRT CR, PR, SD, PD, visually interpreted > 80% decrease in
SUVmax
OS: yes
TMR, tumor to muscle ratio; RFS, relapse free survival; NR, not reported; OS, overall survival; CMR, complete metabolic response; PMR, partial metabolic response; MRglu,
metabolic rate of glucose; pTCP, probability of pathologic tumor control; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
a Between end of treatment and PETscan.
b Patients with a complete response remained locally controlled, while 50% of the patients with a partial or no response showed progression.
c Interval between the end of induction treatment was not reported. The interval between the start of induction chemotherapy and the PETscan was around 83 days.
d Ratio between the SUVmax post induction chemoradiotherapy and the SUVmax after 3 cycles of induction chemotherapy.
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vival.82,124–126 This might be different for FDG-PET scanning, as PET
is more accurate than CT in the distinction of tumor from post-RT
effects109,114,127, and is known to be prognostic for out-
come.87,93,128–130 A prospective study was performed to evaluate
whether PET-CT 3 months after therapy can detect potentially cur-
able progression in locally advanced NSCLC131, which was the case
in a small proportion (3%) of patients, who were all asymptomatic.
An economic evaluation showed that a PET-CT scan 3 months after
(chemo-)radiotherapy is potentially cost-effective, and is more
cost-effective than CT alone.132 As the advantage was confined to
the asymptomatic patients, a PET-CT scan in this group only is
probably as effective and more cost-effective.Other tracers
As response assessment early during and after therapy is com-
plicated by the limited ability of FDG to discriminate between
inflammation and tumor activity, it is worthwhile to investigate
alternative tracers, corresponding more specifically with tumor
proliferative activity.
The uptake of 18F-fluorothymidine (18F-FLT), a marker of DNA syn-
thesis, has been correlated with tumor proliferative activity in various
tumor sites including NSCLC.133–138 Recent (pre)clinical studies have
demonstrated that FLT can detect changes in proliferation during
and after irradiation in colorectal tumors and breast cancer cell
lines.139–141 One pilot study in NSCLC has shown the feasibility of
FLT to image proliferation during chemo-radiotherapy.76
338 J. van Loon et al. / Cancer Treatment Reviews 37 (2011) 331–343Amino-acid tracers theoretically have an advantage over FDG in
that it more specifically accumulates in viable cancer cells.142
However, data on its usefulness in evaluating treatment response
are scarce. One study compared 18F-FDG and the amino-acid tracer
11C-methionine (11C-Met) for evaluation of treatment response in
lung cancer, but this study focussed on early stage patients treated
with stereotactic RT.123 In this study, FDG and Met showed an
equal accumulation in inflammatory tissue, a finding supported
by the results of other research groups.143–145 18F-fluoromethylty-
rosine (18F-FMT), another amino-acid tracer, has recently been put
forward. Two animal studies showed a rapid response to antitumor
therapy, and less accumulation in inflammatory cells.146,147
Clinical implications and future perspectives
The clinical impact of patient selection before or early during
treatment is beyond doubt, as it avoids ineffective treatment with
the associated side-effects and enables alternative therapy in case
of an inadequate early response. Additional research is needed to
define clear cut-off points for FDG uptake to stratify patients into
different treatment modalities. With regard to early response
assessment, attention should be paid to other tracers, in particular
proliferation markers, as they are less susceptible to uptake in
inflammatory tissue.76
A final option for improvement in outcome is the use of PET in
the follow-up. Currently available data do show a potential benefit
of PET in the follow-up compared to CT. Ideally, different follow-up
strategies should be compared in a randomized controlled trial to
provide definitive insight in the added value of PET in the follow-
up of NSCLC patients after combined modality therapy.
Conclusion
In the overall NSCLC patient group, pre-treatment FDG-uptake
is of prognostic value. Results on its ability to predict response to
combined modality therapy in advanced stage NSCLC are conflict-
ing. The most recent study in the largest patient cohort did not
show a significant correlation with survival.
The predictive value of an early metabolic (FDG) response dur-
ing induction chemotherapy has been established. Less is known
about the predictive value of a metabolic response during radical
(chemo-)RT, but the limited available data show a correlation with
survival. The FDG response after radical treatment is of proven
prognostic significance. A time interval of 70 days after the end
of treatment is recommended for response assessment on basis
of the EORTC criteria.
An FDG-PET scan in the follow-up after combined modality
therapy can detect progression amenable for radical retreatment
in a limited number of patients.
Tracers other than FDG are promising for treatment response
assessment, but more research is needed before they can be clini-
cally implemented.Small cell lung cancer (SCLC)
SCLC is a tumor with a poor prognosis, characterized by a rapid
growth rate. Traditionally, staging of those patients has been lim-
ited to the distinction between limited (LD) and extensive disease
(ED).148 Approximately 25% of patients present with limited-dis-
ease (LD), defined as disease confined to one hemithorax, including
the mediastinum and bilateral supraclavicular fossae.149–151 Even
in this patient group, surgery is rarely an option because of the ad-
vanced stage of locoregional disease. Concurrent chemo-radiation
is currently the first choice treatment. Literature is sparse on the
role of PET in LD-SCLC. The available literature suggests that
FDG-PET has additional value above standard staging procedures
in SCLC152–159, with a reported sensitivity and specificity up to100% and 95%.160 Staging with PET can positively influence the out-
come of chemoradiotherapy for LD-SCLC patients by means of
stage migration. Upstaging from LD to ED by FDG-PET scanning oc-
curs in 6–33%152–154,161–164 and downstaging in 3–40%.153,154,161,163
Definition of the tumor volume to be treated
Primary tumor
In order to define the tumor volume, PET should be assessed for
its ability to distinguish malignant from surrounding normal tis-
sue. Studies addressing this issue are focussed on NSCLC.13–16
The same holds true for correlation studies with pathol-
ogy.28,30,31,48,49 Therefore, we can only assume that similar caveats
apply as described above for NSCLC. In short, a major limitation of
PET is the low spatial resolution. Hence, the major gain is to be ex-
pected in regions where anatomical imaging techniques lack the
capacity to discriminate malignant from normal tissue, e.g. in areas
with atelectasis. Another question refers to which method should
be applied for PET-based tumor delineation. Again, comparison
and validation of different methods has exclusively been per-
formed in NSCLC.24,29 No conclusions can be drawn regarding
which method is to be preferred, except that adaptive techniques
are likely to be more accurate than the use of an absolute or rela-
tive SUV-based threshold.22,23 Obviously, blurring effects due to
motion hinder exact tumor delineation. Respiration correlated
imaging techniques have the potential to include individual tumor
motion in the treatment volume, in conjunction with optimal im-
age quality, as blurring effects are significantly reduced.45,46
Microscopic disease extension
As described previously, the only way to define microscopic dis-
ease extension beyond the tumor border visible on imaging is to
correlate imaging with pathology. There are no data on image cor-
relation with pathology available for SCLC.
Lymph nodes
The available data suggest that an FDG-PET scan can identify
metastases to regional lymph nodes in 14–25% of patients whose
mediastinal CT scan is negative.152,156,163 With the high sensitivity
and specificity of PET in SCLC, it is likely that the use of PET scans
improves the coverage of mediastinal lymph node areas in LD-
SCLC.
Until recently, few prospective data concerning selective nodal
irradiation (SNI) in SCLC were available. A report from the Interna-
tional Atomic Energy Agency (IAEA) meeting emphasized the need
for prospective clinical evidence regarding SNI in SCLC.165 CT-
based SNI resulted in an unacceptable amount (11%) of isolated no-
dal failures outside the treatment volume.166 These findings imply
that results on the safety of SNI in NSCLC cannot straightforwardly
be extrapolated to SCLC. Since the publication of the IASLC report,
two studies have become available evaluating FDG-PET-based SNI
in SCLC. In a planning study, a difference in the treatment plan
resulting from PET- and CT-based SNI was found in 24% of pa-
tients.167 Radiation fields increased in 10% and decreased in 14%
of patients, respectively. No significant changes in the radiation
exposure of the normal tissue were observed. In the subsequent
prospective study, 3% of the patients experienced an isolated nodal
failure after a minimal follow-up of 18 months, comparable to re-
sults in NSCLC. A remarkably low percentage (12%) of grade III
esophagitis was found, while this occurs in about 30% of patients
receiving elective nodal irradiation or CT-based SNI.166,168 This
finding deserves further investigation. The low rate of isolated no-
dal failures and toxicity thus supports the use of PET-based SNI in
LD-SCLC.
A few points of caution should be taken into consideration. First,
incidental irradiation of surrounding nodal stations might partially
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results should be re-evaluated with the application of more confor-
mal techniques (SBRT, IMRT, particle therapy). A second point of
attention consists of the methods for target volume definition. In
the available study, the mediastinal nodal regions involved on
PET were included in the treatment field.169 As our literature
search did not yield any study evaluating autocontouring methods
for lymph node delineation in SCLC, we recommend SNI of the
whole mediastinal nodal station involved on PET.
Clinical implications and future perspectives
As in most SCLC cases, the bulk of disease is located in the hilar
and mediastinal regions, reduction of the treatment volume can
mainly be reached by omitting elective nodal irradiation. If the
finding of low esophageal toxicity, as described in the first study
with PET-based SNI169 holds true, PET based SNI indeed provides
opportunities for treatment intensification. With regard to RT plan-
ning, another point of consideration is the concept of subboosting
areas of supposed radioresistance. FDG-PET, as well as PET with
other tracers, could help to identify those regions within the tu-
mor. Although this concept is readily evolving in NSCLC, no such
trend is observed until now in SCLC. Although it is reasonable to as-
sume that characteristics associated with radioresistance are also
heterogeneous in SCLC33–35, the distribution of the disease load
in NSCLC is different from SCLC, as for most SCLC cases, the major-
ity of the tumor load is found in the nodal stations. Studies on the
evolution and stability of regions with high FDG-uptake in NSCLC
are entirely focussed on the primary tumor, and no such informa-
tion is available with respect to lymph nodes. These issues should
be addressed when heterogeneous dose escalation is taken into
consideration in SCLC.
Conclusion
There are no data available on the role of FDG-PET in defining
the borders of the primary tumor. In contrast with CT-based SNI,
first results indicate that SNI of FDG-PET positive nodal stations ap-
pears to be safe and results in remarkably limited toxicity. With
the increased use of more conformal radiation techniques, the
safety of PET-based SNI should be re-evaluated. It is recommended
to encompass the whole anatomical mediastinal region containing
FDG-positive nodes in the treatment volume.
Outcome prediction on basis of PET before or early after the start of
treatment, and the prognostic value of PET after therapy
The majority of SCLC patients still shows disease progression
short after the completion of chemoradiotherapy, with over 30%
having an isolated local recurrence as their first site of progres-
sion.168 Furthermore, the treatment is associated with considerable
toxicity, with grade 3 esophagitis in up to 27% of patients.117,170–172
Therefore, the ability to predict the benefit from treatment would
be of great clinical value. Recent data have made clear that the tra-
ditional staging system with two categories (limited and extensive
disease) is on its own not an adequate predictor of survival and is
not sufficient to stratify patients for the most optimal ther-
apy.173,174 Since recently, it is recommended to use the TNM stag-
ing for SCLC, as it has proven to result in a better stratification of
patients in prognostic subgroups.175,176 FDG uptake on PET before,
during or after therapy could have a role as additional prognostic
and predictive marker in SCLC.
Prognostic value of pre-treatment PET
Evidence concerning the prognostic value of FDG-uptake before
treatment in SCLC is scarce. One study was identified that ad-
dressed this subject.177 The majority of patients had LD and were
treated with concurrent chemoradiotherapy. Overall, as well asfor the subgroup with LD, patients with a high SUVmax (i.e., higher
than the median) had a significantly worse overall survival than
patients with a low SUVmax (LD: 20.1 vs. 35.3 months). Three prog-
nostic subgroups could be defined on basis of FDG-uptake and dis-
ease stage. Those results imply that different treatment strategies
are required for LD with low and high SUVmax. Randomized clinical
studies are warranted to answer whether FDG-uptake in combina-
tion with anatomical staging is predictive of outcome and can be
used to select the appropriate therapy for each patient group.Outcome prediction on basis of early PET response during combined
modality treatment
The predictive ability of an FDG response early after the start of
chemotherapy has been evaluated in two studies, both after one
cycle of chemotherapy.178,179 However, patients with both LD
and ED were investigated. Therefore, the results reflect the predic-
tive value of an FDG response early during palliative chemotherapy
or radical chemoradiotherapy. Furthermore, both studies used CT
response after completion of therapy as a reference, and not sur-
vival. Both studies concluded that the metabolic response was cor-
related with the response according to RECIST.
Several important questions need to be addressed in future
studies to make early response assessment with PET during treat-
ment a valuable clinical tool. Those questions include the type of
measurement, the definition for response, and the most optimal
time interval for the measurement of early response. Regarding re-
sponse criteria, the use of the EORTC recommendations108, a 20%
threshold96, as well as the criteria for visual response assessment
by MacManus are valid109: Fischer et al. compared the visual meth-
od with the EORTC criteria in SCLC response evaluation after one
cycle of chemotherapy and found no significant difference.178
Regarding the type of measurement and the time interval, no sep-
arate data on SCLC are available. As long as no such data are avail-
able, the most practical alternative is to adhere to the NSCLC
recommendations. Those are the use of relatively simple semi-
quantitative measurements such as SUVmax95–97, and a time inter-
val of 1–3 cycles of chemotherapy.95–97
Caution is warranted, however, when projecting results ob-
tained in NSCLC at SCLC. As mentioned before, those are two dis-
tinct types of disease with different clinical behavior. SCLC is
characterized by a rapid response to chemo- and radiotherapy.
Therefore, a response to therapy could be more rapidly visible on
CT than it is in NSCLC, which might restrict the beneficial effect
of PET. This hypothesis is supported by the study of Fischer et al.,
who found that early response assessment after one cycle of che-
motherapy with CT and PET showed a comparable correlation with
the final evaluation on basis of RECIST.178Added value of PET after combined modality treatment
Two retrospective studies evaluated the prognostic value of PET
after treatment in SCLC patients157,180, with one specifically aimed
at LD.180 The first study included both LD and ED, and both treated
and untreated patients, with treated LD patients representing 50%
of the study population. It is hard to draw separate conclusions on
this group, but overall, there was a significant negative correlation
between PET positivity or SUVmax and overall survival.157
The study evaluating exclusively LD patients has some limita-
tions: only 73% was treated with chemoradiotherapy, the remain-
ing patients with palliative chemotherapy.180 Furthermore, the
time interval between the end of treatment and PET-scanning
was variable (3–125 days). Finally, the definition of PET positivity
was rather broad. With those limitations in mind, the study
showed a significant difference in progression free survival be-
tween PET positive and negative patients, with a trend for overall
survival.
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on the final outcome is that progression should be detected at a
time that radical retreatment is still an option. The rapid growth
rate and early dissemination make it less likely for progression to
be detected in a ‘‘curable’’ stage in SCLC than in NSCLC. Although
no studies have addressed the role of FDG-PET in the follow-up
of SCLC, it can therefore be questioned whether PET scanning is
advantageous with respect to outcome.
Clinical implications and future perspectives
It is obvious that the currently available data are insufficient to
modify or adapt treatment on basis of pre-treatment FDG uptake or
an early metabolic response in SCLC patients. Research in the field
of early response assessment is of particular importance to define
the additional benefit of PET above CT given the rapid response of
SCLC to chemo- and radiotherapy.
Finally, the role of PET after combined modality therapy of LD-
SCLC should be addressed. Given the early dissemination of SCLC,
most benefit is to be expected with a tracer that allows response
evaluation early after treatment. Given the high uptake in inflam-
matory regions, FDG might not be ideal for this purpose. Therefore,
other tracers should be evaluated.
Conclusion
Studies evaluating the prognostic value of PET, its ability to pre-
dict response to combined modality treatment and the added value
of PET after treatment in SCLC are scarce. Available results mainly
come from studies in patients with both limited and extensive dis-
ease. Overall, results do show some predictive value of an FDG re-
sponse before and during therapy, as well as prognostic value of
FDG uptake after treatment. No studies have evaluated the impact
of PET in the follow-up of SCLC.
General conclusions
Molecular imaging with PET, using different tracers, has the po-
tential to distinguish between vital tumor and non-malignant tis-
sue and to identify intra-tumor characteristics. The additional
value of FDG-PET in defining the primary tumor volume has been
established, mainly in regions with atelectasis or post-treatment
effects. Three dimensional models that correlate imaging findings
with pathology are being developed for NSCLC, which could allow
validation of different thresholds for SUV-based contouring, evalu-
ation of microscopic spread and intra-tumor heterogeneity. FDG-
PET has the ability to identify regions within the tumor that are
associated with radioresistance, and it has been proved that these
regions remain stable during a radiotherapy course. Therefore,
boosting of radioresistant areas identified with FDG-PET appears
to be feasible and is subject of current research. Selective irradia-
tion of FDG-PET positive nodal stations in NSCLC is safe and leads
to decreased normal tissue exposure, providing opportunities for
dose escalation. For this reason, it is the preferred treatment in
NSCLC. First results in SCLC suggest that the same holds true for
SCLC. Data on the predictive value of pre-treatment FDG-uptake
and an early metabolic response during combined modality treat-
ment are conflicting and limited, respectively. The FDG response
after radical treatment is of prognostic significance. A time interval
of 70 days between end of treatment and PET scanning is recom-
mended for response evaluation in NSCLC. A PET scan in the fol-
low-up of NSCLC potentially improves survival through the
detection of progression with radical treatment options. Data on
its value in the follow-up of SCLC are lacking.
Tracers other than 18FDG are promising for treatment response
assessment and the visualization of intra-tumor heterogeneity, but
more research is needed before they can be clinically implemented.References
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